Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severity of Chronic Kidney Disease and Outcomes After Admission to the Intensive Care Unit.

JAMA network open·2026
Same author

Systematic Review and Meta-Analysis of Intensive Care Unit Scoring Systems' Performance in Patients with Pre-Existing Kidney Disease.

Kidney international reports·2026
Same author

Eating disorder-related electrolyte abnormalities and adverse outcomes: A systematic review and meta-analysis.

PloS one·2026
Same author

Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.

Journal of the American Heart Association·2026
Same author

Development and Validation of a Canadian Prediction Equation for Incident CKD Using Population-Based, Administrative Data.

Canadian journal of kidney health and disease·2026
Same author

Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment, and Control: A Population-based Cohort Study.

The Canadian journal of cardiology·2026
Same journal

New Drugs on the Horizon for Hypertension.

Advances in kidney disease and health·2026
Same journal

Hyperammonemia Physiology and Management: A Nephrology-Centered Review.

Advances in kidney disease and health·2026
Same journal

Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?

Advances in kidney disease and health·2026
Same journal

Social Determinants of Health and Primary Hypertension in Children and Adolescents: Proposed Solutions Using a Socioecological Model of Health.

Advances in kidney disease and health·2026
Same journal

Blood Pressure Management in the Inpatient and Acute Care Setting.

Advances in kidney disease and health·2026
Same journal

Endocrine Hypertension in Children and Adults: Beyond Primary Aldosteronism.

Advances in kidney disease and health·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Primary Aldosteronism and the Kidneys.

Emily L Simms1, Gregory L Hundemer1

  • 1Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, Ontario, Canada.

Advances in Kidney Disease and Health
|July 3, 2026
PubMed
Summary
This summary is machine-generated.

Primary aldosteronism (PA), a common cause of secondary hypertension, significantly harms kidney health. Early diagnosis and treatment, including surgery or medication, protect kidneys but may reveal underlying chronic kidney disease (CKD).

Keywords:
AldosteroneChronic kidney diseaseHyperfiltrationHypertensionPrimary aldosteronism

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

  • Nephrology
  • Endocrinology
  • Hypertension Research

Background:

  • Primary aldosteronism (PA) is the most common cause of secondary hypertension, affecting 5-10% of hypertensive patients.
  • PA involves autonomous aldosterone secretion, leading to detrimental cardiovascular and kidney effects.
  • Kidney manifestations include glomerular hyperfiltration, albuminuria, accelerated GFR decline, and increased CKD risk.

Purpose of the Study:

  • To discuss diagnostic and treatment approaches for PA.
  • To highlight kidney manifestations associated with PA and its therapies.
  • To present a teaching case illustrating PA management and renal outcomes.

Main Methods:

  • Case discussion format.
  • Review of PA pathophysiology and clinical impact on kidneys.
  • Analysis of diagnostic and therapeutic strategies for PA.

Main Results:

  • PA significantly contributes to kidney disease progression, including CKD.
  • Targeted therapies (adrenalectomy, MRAs) mitigate kidney risks associated with PA.
  • Treatment can unmask pre-existing CKD by reversing PA-induced hyperfiltration.

Conclusions:

  • Early diagnosis and treatment of PA are crucial for kidney protection.
  • Understanding PA's renal impact is essential for effective patient management.
  • Mineralocorticoid receptor antagonists and surgery offer long-term kidney benefits in PA.